Agile Therapeutics, Inc.
AGRX

$10.43 M
Marketcap
$1.51
Share price
Country
$0.05
Change (1 day)
$2.63
Year High
$0.20
Year Low

Agile Therapeutics, Inc., a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was incorporated in 1997 and is headquartered in Princeton, New Jersey.

marketcap

Earnings for Agile Therapeutics, Inc. (AGRX)

Earnings in 2023 (TTM): $-14,465,000

According to Agile Therapeutics, Inc.'s latest financial reports the company's current earnings (TTM) are $-14,465,000. The earnings displayed on this page is the company's Pretax Income.

Earnings history of Agile Therapeutics, Inc.

Annual Earnings

Year Income Before Tax Net Income
2023 $-14,465,000 $-14,465,000
2022 $-30,087,000 $-25,412,000
2021 $-74,894,000 $-76,585,000
2020 $-51,853,000 $-54,686,000
2019 $-18,606,000 $-18,443,000
2018 $-20,256,000 $-19,779,000
2017 $-28,304,000 $-28,304,000
2016 $-31,816,000 $-28,741,000
2015 $-36,307,000 $-30,335,000
2014 $-19,730,000 $-16,077,000
2013 $-14,320,620 $-14,320,620
2012 $-23,260,127 $-23,260,127